FY20 ends on a high; cost base to increase in FY21
24/02/21 -"FY20 sales and operating profit targets were exceeded, led by higher Darzalex royalties and lower R&D costs. Given its convenience dosing, Darzalex should hit the $5bn sales mark in FY21 (vs. ..."
Pages
48
Language
English
Published on
24/02/21
You may also be interested by these reports :
19/12/25
The change in the target price is due to a change in the analyst covering the stock, complemented by the usage of systematic intrinsic and peer-based ...
17/12/25
Since Bayer’s shares have already surged 87% ytd, recovering to their highest levels in the last two years, we do not foresee a material upside ...
12/12/25
Eli Lilly’s Retatrutide grabbed headlines with c.29% weight-loss efficacy in late-stage trials for obese patients who also had knee osteoarthritis. ...
08/12/25
Despite US tariff threats, drug pricing pressures and the persistent insistence from the US government to reshore manufacturing, the AV Big Pharmas ...